ETR:BAYN Bayer Aktiengesellschaft (BAYN) Stock Price, News & Analysis €56.52 -0.04 (-0.07%) As of 11/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About Bayer Aktiengesellschaft Stock (ETR:BAYN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BAYN alerts:Sign Up Key Stats Today's Range€56.40▼€56.9850-Day Range€42.59▼€57.0852-Week Range€24.96▼€44.28Volume1.89 million shsAverage VolumeN/AMarket Capitalization€57.06 billionP/E RatioN/ADividend Yield0.19%Price TargetN/AConsensus RatingN/A Company Overview Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. The Crop Science segment offers seeds, improved plant traits, innovative chemical and biological crop protection products, digital solutions, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany. Read More Receive BAYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bayer Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BAYN Stock News HeadlinesBayer Remains in Demand After US ApprovalNovember 10, 2026 | marketscreener.comMBayer Secures FDA Nod For SUNHARBO In Secondary Stroke PreventionNovember 10, 2026 | rttnews.comFDA clears next-gen therapy with 10 to 40 times greater potencyTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer cells - and early human data revealed up to a 63.7 percent reduction in cancer burden. One NASDAQ-listed biotech's TriKE platform is designed to keep these immune cells locked onto tumors longer. Its next-generation version, showing potential for 10 to 40 times greater potency, has just cleared an important FDA milestone.November 16 at 1:00 AM | Market Tactic (Ad)Bayer's blood thinner Sunharbo also approved in the USNovember 9, 2026 | marketscreener.comMBayer gets Chinese green light for sevabertinibNovember 5, 2026 | marketscreener.comMBayer AG : UBS reiterates its Buy ratingNovember 4, 2026 | marketscreener.comMBayer AG : Goldman Sachs gives a Buy ratingNovember 4, 2026 | marketscreener.comMBayer Aktiengesellschaft Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 4, 2026 | marketscreener.comMSee More Headlines BAYN Stock Analysis - Frequently Asked Questions How have BAYN shares performed this year? Bayer Aktiengesellschaft's stock was trading at €37.01 at the beginning of 2026. Since then, BAYN stock has increased by 52.7% and is now trading at €56.52. What other stocks do shareholders of Bayer Aktiengesellschaft own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bayer Aktiengesellschaft investors own include NVIDIA (NVDA), Alibaba Group (BABA), Basf (BAS), AT&T (T), GE Aerospace (GE), Micron Technology (MU) and Walmart (WMT). Industry, Sector and Symbol Stock ExchangeETR SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolETR:BAYN CIKN/A Webwww.bayer.com Phone49 214 30 1FaxN/AEmployees87,830Year FoundedN/AProfitability EPS (Trailing Twelve Months)(€0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth36.39Net Income-€904.33 million Net Margins-3.16% Pretax MarginN/A Return on Equity-5.10% Return on Assets3.71% Debt Debt-to-Equity Ratio148.84 Current Ratio1.35 Quick Ratio0.72 Sales & Book Value Annual Sales€45.77 billion Price / Sales1.25 Cash Flow€9.87 per share Price / Cash Flow5.73 Book Value€32.88 per share Price / Book1.72Miscellaneous Outstanding Shares1,009,583,481Free FloatN/AMarket Cap€57.06 billion OptionableNot Optionable Beta0.81 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (ETR:BAYN) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredFDA clears next-gen therapy with 10 to 40 times greater potencyTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bayer Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Share Bayer Aktiengesellschaft With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.